They're completely unregulated, carry risks including nausea, facial flushing, and potentially more serious effects on blood pressure and heart rate
A growing number of adults are looking for safe and effective alternatives to traditional growth hormone therapy, and as such, interest in peptides like CJC-1295 have increased Google search trends shows consistent growth over the last five years
With expert healthcare professionals, personalized support, and practical tools like the GLP-1 Budget Builder, Levity empowers you to achieve safe and sustainable results
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8